Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations

Autor: Vreman, Rick A., Mantel-Teeuwisse, Aukje K., Hövels, Anke M., Leufkens, Hubert G.M., Goettsch, Wim G., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Přispěvatelé: Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Cross-Cultural Comparison
medicine.medical_specialty
procedure
Technology Assessment
Biomedical
Cost-Benefit Analysis
education
Clinical Decision-Making
Choice Behavior
03 medical and health sciences
0302 clinical medicine
parasitic diseases
medicine
Humans
cost-effectiveness assessment
process
030212 general & internal medicine
Culturally Appropriate Technology
health technology assessment
relative-effectiveness assessment
Healthcare Disparities
Practice Patterns
Physicians'
Policy Making
Reimbursement
conditional marketing authorization
Health Care Rationing
business.industry
evidence
030503 health policy & services
differences
Health Policy
Environmental and Occupational Health
Public Health
Environmental and Occupational Health
Health technology
regulation
Health Care Costs
Culturally Competent Care
reimbursement
practice
Europe
Family medicine
Cohort
Public Health
0305 other medical science
business
Inclusion (education)
Zdroj: Value in Health, 23(1), 10. Elsevier Ltd
ISSN: 1098-3015
Popis: Background: Health technology assessment (HTA) plays an important role in reimbursement decision-making in many countries, but recommendations vary widely throughout jurisdictions, even for the same drug. This variation may be due to differences in the weighing of evidence or differences in the processes or procedures, which are known as HTA practices. Objective: To provide insight into the effects of differences in practices on interpretation of intercountry differences in HTA recommendations for conditionally approved drugs. Methods: HTA recommendations for conditionally approved drugs (N = 27) up until June 2017 from England/Wales, France, Germany, the Netherlands, and Scotland were included. Recommendations and practice characteristics were extracted from these five jurisdictions and this data was validated. The effect of nonsubmissions, resubmissions, and reassessments; cost-effectiveness assessments; and price negotiations on changes in the percentage of negative recommendations and the interpretation of intercountry differences in HTA outcomes were analyzed using Fisher exact tests. Results: The inclusion of cost-effectiveness assessments led to significant increases in the proportion of negative recommendations in England/Wales (from 4% to 50%, P
Databáze: OpenAIRE
Externí odkaz: